How should a 41-year-old female with a history of drug use presenting to the emergency department with severe hypertension, sweating, agitation, runny nose, a Clinical Opiate Withdrawal Scale (COWS) score of 20, inability to swallow oral medications, and a 0.3 mg clonidine patch be managed in the emergency department?

Management of Severe Opioid Withdrawal with Inability to Swallow

Given this patient's COWS score of 20 (severe withdrawal), inability to swallow, and persistent hypertension despite clonidine, you should administer sublingual buprenorphine 4-8 mg immediately, as it does not require swallowing and is the most effective treatment for severe opioid withdrawal in the ED setting. 1

Immediate Management Algorithm

1. Buprenorphine Administration (First-Line)

• Administer 4-8 mg sublingual buprenorphine based on withdrawal severity (COWS 20 = severe) 1
• Sublingual formulation dissolves under the tongue—does not require swallowing
• Reassess COWS score after 30-60 minutes
• Target total dose of 16 mg for most patients with severe withdrawal 1
• Any DEA-licensed physician can administer (not prescribe) buprenorphine in the ED for up to 72 hours without X-waiver 1

Key advantage: Buprenorphine is superior to methadone in this scenario because:

• It has a ceiling effect on respiratory depression (safer profile) 1
• Shorter duration of action reduces risk if patient uses additional opioids post-discharge 1
• Level C recommendation: preferentially use buprenorphine over methadone 1

2. Blood Pressure Management

• Continue clonidine patch (already applied)
• Add IV antihypertensives for BP 158/110 (still elevated):
  • Consider IV labetalol or hydralazine for acute control
  • Clonidine patch takes 2-3 days to reach therapeutic levels 2
  • Patch provides sustained effect but inadequate for acute crisis

3. Adjunctive Symptomatic Treatment

Since patient cannot swallow, use parenteral/sublingual alternatives:

• Antiemetics: IV ondansetron or promethazine for nausea 1
• Benzodiazepines: IV lorazepam for agitation and anxiety (helps reduce catecholamine release) 1
• IV fluids: for hydration and supportive care

4. Alternative if Buprenorphine Unavailable

If buprenorphine is not available:

• IM olanzapine 10 mg is superior to oral clonidine for withdrawal symptoms (27% vs 63% requiring rescue medication) 3
• Does not require swallowing
• Reduces COWS score by 8.3 points vs 5.1 with clonidine 3

Critical Timing Considerations

Confirm time since last opioid use before buprenorphine:

• Short-acting opioids (heroin): >12 hours 1
• Extended-release formulations: >24 hours 1
• Methadone maintenance: >72 hours 1

With COWS 20, the patient is clearly in severe withdrawal, making precipitated withdrawal from buprenorphine unlikely. However, if fentanyl is involved, be aware that lower urine fentanyl concentrations correlate with more severe withdrawal 4, suggesting the patient may be further from last use than reported.

Common Pitfalls to Avoid

1. Don't wait for oral methadone capability—the patient cannot swallow and buprenorphine is preferred anyway 1

2. Don't rely solely on clonidine patch—it's inadequate for severe withdrawal (COWS >8 requires opioid agonist therapy) 1. Level B recommendation: buprenorphine/methadone are more effective than α2-agonists alone 1

3. Don't underdose buprenorphine—with COWS 20, start with 8 mg and titrate to 16 mg total 1

4. Don't discharge without arranging follow-up—provide written referral information for ongoing addiction treatment 1

Disposition Planning

• Reassess after buprenorphine administration (30-60 minutes)
• If X-waivered: prescribe buprenorphine/naloxone 16 mg daily for 3-7 days 1
• If not X-waivered: patient may return for up to 3 consecutive days for interim treatment 1
• Provide naloxone prescription/kit for overdose reversal 5
• Arrange outpatient addiction treatment follow-up

The combination of sublingual buprenorphine (which doesn't require swallowing), IV antihypertensives, IV benzodiazepines for agitation, and IV antiemetics addresses all of this patient's acute needs while providing the most effective evidence-based treatment for severe opioid withdrawal. 1